News

Gamida Cell Ltd. and Be The Match BioTherapies, a subsidiary of the National Marrow Donor Program/Be The Match offering integrated platforms and software to manage the collection and…
Read More...

GlaxoSmithKline plc announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash…
Read More...

Vertex Pharmaceuticals (Europe) Limited announced that the European Commission has granted approval of the label extension for ORKAMBI (lumacaftor/ivacaftor) for the treatment of…
Read More...

Alnylam Pharmaceuticals and Medison Pharma announced an exclusive agreement to commercialize ONPATTRO, the first-ever commercialized RNAi therapeutic, as well as other investigational…
Read More...

Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ONTRUZANT (trastuzumab-dttb), a biosimilar referencing HERCEPTIN (trastuzumab), across…
Read More...

The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of…
Read More...

AstraZeneca announced that its partner Ironwood Pharmaceuticals, Inc. has received marketing authorisation from the National Medical Products Administration (NMPA) for Linzess…
Read More...

The SCHOTT technology group is set to invest around 300 million euros in the next three years in the expansion of its core business of glass tubing as the starting material for…
Read More...

AMAG Pharmaceuticals announced that it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this…
Read More...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) accepted for filing the company’s New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin…
Read More...

BioMed X announced a new crowdsourcing project within its framework collaboration with Boehringer Ingelheim. BioMed X and Boehringer Ingelheim started their partnership in 2014 and…
Read More...

Aerpio Pharmaceuticals announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead…
Read More...

Zymeworks reported the achievement of a new development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2014 licensing and collaboration…
Read More...

Lipocine Inc. announced approximately eight-week top-line interim results from an ongoing sixteen-week Liver Fat Imaging study ("Liver Fat Study") with LPCN 1144. The Liver Fat Study is…
Read More...

Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse platform technology for antibody drug discovery, announced the expansion of its existing non-exclusive…
Read More...

AIVITA Biomedical announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1B clinical trial investigating the…
Read More...

Nexus Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company's AP-rated therapeutic equivalent for Busulfex 60 mg/10…
Read More...

Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma's Xuezhikang Capsules in…
Read More...

Phoenix Molecular Designs announced that it has entered into a collaboration with Roche to develop a diagnostic (CDx) in triple-negative breast cancer (TNBC). The Roche CDx identifies…
Read More...

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an…
Read More...